Related references
Note: Only part of the references are listed.Emerging immunotherapy or HCC: A guide for hepatologists
Friedrich Foerster et al.
HEPATOLOGY (2022)
Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice
Bernd Heinrich et al.
GASTROENTEROLOGY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)
Philipp K. Haber et al.
GASTROENTEROLOGY (2021)
Hepatocellular Carcinoma - Origins and Outcomes
Robin K. Kelley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
mRECIST for HCC: Performance and novel refinements
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)